Primaa and PathPresenter announced completion of their joint validation study of Cleo Skin, Primaa's dermatopathology AI, running inside PathPresenter's FDA cleared clinical viewer. The study covered a realistic case mix of melanoma, naevus, squamous cell carcinoma, basal cell carcinoma and benign lesions, and the companies report faster and more consistent diagnostic reporting when the AI populates structured reporting fields inside the viewer. Interim phase one results PathPresenter published in March reported a 25 percent reduction in analysis time and a 6 percent improvement in diagnostic accuracy with the model, with higher interobserver agreement on lesion classification.
Our readThe finding worth holding onto is that the gains came from the AI being inside the viewer rather than beside it, which is the deployment shape most labs still have not achieved. The evidence is vendor and partner reported, with the population and endpoints described at summary level, so treat it as a workflow study rather than a diagnostic accuracy trial until the full results are published, and ask which of the interim numbers held at completion.